Alisporivir (ALV) plus Peg-interferon/Ribavirin (PR) achieves high on-treatment undetectable HCV RNA levels among the most difficult to treat HCV G1 patients. Results of a planned treatment week 24 interim analysis of a randomized, double blind, placebo controlled trial (FUNDAMENTAL study)